The ACHIEVE trial

ACHIEVE is the only randomised trial designed with this as its main question: whether treating hearing loss slows the decline in memory and thinking that comes with age. Overall it missed: three years of hearing aids and counselling did no better than health education. A benefit showed up only in a higher-risk subgroup, which makes it a lead worth testing, not proof that hearing aids protect the brain.

Treat hearing loss because it improves conversation, work and social life. Don't count on hearing aids to prevent dementia on the strength of this trial.

What the trial tested

ACHIEVE enrolled 977 adults aged 70–84 with untreated hearing loss and no substantial cognitive impairment, at four community sites across the USA. Half were randomly assigned to a hearing intervention, which meant audiological counselling plus hearing aids; the other half to health education sessions on preventing chronic disease. Participants knew which group they were in.

The main goal was the 3-year change in an overall cognition score built from a full battery of memory and thinking tests. Dementia itself was not the endpoint.

The participants came from two very different groups. 238 were drawn from the Atherosclerosis Risk in Communities (ARIC) study, a long-running US heart study; they were older, had more risk factors for cognitive decline and scored lower at the start. The other 739 were healthy volunteers recruited from the community.^[1]

The main result was null

Across all 977 people, cognitive decline over three years was essentially identical in the two groups. Neither intervention caused significant side effects.^[2]

The subgroup everyone quotes

In the 238 higher-risk participants from the heart study, decline was about 48% slower with the hearing intervention. This was a planned comparison, and the difference between the two groups' responses was statistically significant. It is still a subgroup of a trial that missed its main goal, and in the 739 healthy volunteers there was no benefit.^[3]

A later analysis of the same trial sorted participants after the fact by their predicted risk of decline. In the top quarter, 3-year decline was 61.6% slower with the hearing intervention, with a wide margin of uncertainty (33.7% to 94.1%).^[4] That fits the idea that hearing care helps most in people already at higher risk, but a re-analysis of a null trial generates a hypothesis; it doesn't confirm one.

What it found on loneliness

The trial also looked at social life, as exploratory outcomes. Over three years, the hearing intervention reduced loneliness and slowed the shrinking of people's social networks, by about one person — small changes the authors say may not be clinically meaningful.^[5] Social isolation counts as a dementia risk factor in its own right, so this is one plausible route by which hearing care could matter, but it was not what the trial was designed to test.

What it doesn't show

Nothing about dementia diagnoses. The outcome was 3-year change in test scores. The supportive dementia evidence is observational: an Australian analysis built to mimic a trial, and pooled cohort studies, both covered on Hearing.
Nothing about younger people. Everyone was 70 or older.
Nothing about whether the higher-risk benefit is real. That needs a trial designed around people at higher risk.

What to do

Get tested and treat hearing loss for the everyday benefits, which randomised trials of hearing aids do show.^[6]
Wear it regularly. In observational studies, lower dementia risk appears only in people who say the aid actually improved their hearing.
Treat dementia protection as probable at best, not proven. The wider set of risk factors is on Dementia prevention.